Jump to content

Talk:WuXi AppTec

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by AM WuXi (talk | contribs) at 18:52, 3 January 2024 (* Updates to the article */ added an additional request.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

WikiProject iconCompanies Start‑class Low‑importance
WikiProject iconThis article is within the scope of WikiProject Companies, a collaborative effort to improve the coverage of companies on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.CompaniesWikipedia:WikiProject CompaniesTemplate:WikiProject Companiescompany articles
StartThis article has been rated as Start-class on Wikipedia's content assessment scale.
LowThis article has been rated as Low-importance on the project's importance scale.
WikiProject Companies To-do:
Here are some tasks awaiting attention:

Updates to the article

Hi, I would like to suggest some updates to the article based on the company's activities in recent years. Please add:

  • In the History section - In 2019, WuXi AppTec acquired Pharmapace, a clinical services company in San Diego, expanding WuXi AppTec's drug development and biometrics capabilities.[1] In 2021, WuXi STA purchased a Bristol Myers Squibb drug product manufacturing facility in Switzerland, adding to WuXi STA's global services.[2] The same year, WuXi AppTec acquired the UK-based R&D contract company, OXGENE, and created WuXi ATU, a CDMO subsidiary focusing on cell therapy and gene therapy.[3] WuXi ATU opened a testing center in Philadelphia.[4] In 2022, the WuXi STA Changzhou production campus initiated oligonucleotide and peptide manufacturing to expand cell and gene therapy advancements.[5]

Additionally, the different WuXi AppTec entities are inaccurate in the article. See this source to explain the rename and the correct entities under the WuXi AppTec umbrella. As far as I understand, based on the guidelines, this would be an uncontroversial edit for me to do. As it is a bit labor-intensive, I am happy to go in and do it myself with the community's approval.

References

  1. ^ Adams, Ben (8 May 2019). "China's WuXi AppTec buys up U.S. Pharmapace, boosting biometrics offering". fiercebiotech.com.
  2. ^ "WuXi STA completes acquisition of Bristol Myers Squibb manufacturing facility in Switzerland". 3 August 2021.
  3. ^ "OXGENE Eyes Further Growth in Cell and Gene Therapy Services after Acquisition by WuXi AppTec". genedgenews.com. 3 March 2021.
  4. ^ MacDonald, Gareth (7 December 2021). "WuXi ATU opens cell and gene therapy testing center". bioprocessintl.com.
  5. ^ Keenan, Joseph (7 July 2022). "WuXi unveils new production capabilities at Changzhou campus amid expansion push". fiercepharma.com.

Thank you very much.AM WuXi (talk) 18:51, 3 January 2024 (UTC)[reply]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Talk:WuXi_AppTec&oldid=1193418582"